Novo Nordisk shares dive after heart medicine fails trial, dealing another blow to its pipeline
The experimental medicine ziltivekimab didn't translate into a statistically meaningful reduction in major cardiovascular adverse events, Novo said Friday.
What's Your Reaction?
Like
0
Dislike
0
Love
0
Funny
0
Angry
0
Sad
0
Wow
0
